InvestorsHub Logo
Followers 840
Posts 120470
Boards Moderated 18
Alias Born 09/05/2002

Re: jsmith77 post# 564

Monday, 01/09/2017 9:47:24 AM

Monday, January 09, 2017 9:47:24 AM

Post# of 592
This was the first 2017 guidance for Bendeka/Treanda, so it wasn't actually lowered, but it was lower than investors expected. TEVA didn't give a reason for the low guidance, and no one on the hour-long CC last week asked about it.

My assumption is that the NHL/CLL arena is becoming more competitive with several newly approved drugs, which is reducing Bendeka/Treanda's market share.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EGRX News